Imperial College London
Professor Robert Wilkinson

ProfessorRobertWilkinson

Faculty of Medicine, Department of Infectious Disease

Professor in Infectious Diseases
 
 
 
//

Contact

 

r.j.wilkinson Website

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Spies:2022:10.4102/sajhivmed.v23i1.1396,
author = {Spies, R and Schutz, C and Ward, A and Balfour, A and Shey, M and Nicol, M and Burton, R and Sossen, B and Wilkinson, R and Barr, D and Meintjes, G},
doi = {10.4102/sajhivmed.v23i1.1396},
journal = {Southern African Journal of HIV Medicine},
title = {Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis},
url = {http://dx.doi.org/10.4102/sajhivmed.v23i1.1396},
volume = {23},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Patients with HIV and drug-resistant tuberculosis (TB) are at high risk of death. Objectives: We investigated the association between rifampicin-resistant TB (RR-TB) and mortality in a cohort of patients who were admitted to hospital at the time of TB diagnosis. Method: Adults hospitalised at Khayelitsha Hospital and diagnosed with HIV-associated TB during admission, were enrolled between 2013 and 2016. Clinical, biochemical and microbiological data were prospectively collected and participants were followed up for 12 weeks. Results: Participants with microbiologically confirmed TB (n = 482) were enrolled a median of two days (interquartile range [IQR]: 1-3 days) following admission. Fifty-three participants (11.0%) had RR-TB. Participants with rifampicin-susceptible TB (RS-TB) received appropriate treatment a median of one day (IQR: 1-2 days) following enrolment compared to three days (IQR: 1-9 days) in participants with RR-TB. Eight participants with RS-TB (1.9%) and six participants with RR-TB (11.3%) died prior to the initiation of appropriate treatment. Mortality at 12 weeks was 87/429 (20.3%) in the RS-TB group and 21/53 (39.6%) in the RR-TB group. RR-TB was a significant predictor of 12-week mortality (hazard ratio: 1.88; 95% confidence interval: 1.07-3.29; P = 0.03). Conclusion: Mortality at 12 weeks in participants with RR-TB was high compared to participants with RS-TB. Delays in the initiation of appropriate treatment and poorer regimen efficacy are proposed as contributors to higher mortality in hospitalised patients with HIV and RR-TB.
AU  - Spies,R
AU  - Schutz,C
AU  - Ward,A
AU  - Balfour,A
AU  - Shey,M
AU  - Nicol,M
AU  - Burton,R
AU  - Sossen,B
AU  - Wilkinson,R
AU  - Barr,D
AU  - Meintjes,G
DO  - 10.4102/sajhivmed.v23i1.1396
PY  - 2022///
SN  - 1608-9693
TI  - Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis
T2  - Southern African Journal of HIV Medicine
UR  - http://dx.doi.org/10.4102/sajhivmed.v23i1.1396
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36299556
UR  - http://hdl.handle.net/10044/1/100478
VL  - 23
ER  -
Download